New Jersey-Based Celsion’s ThermoDox Phase III Failure Deals Blow To China’s Hisun
This article was originally published in The Pink Sheet Daily
With the ink barely dry in a deal between U.S. biotech Celsion and Chinese active ingredient manufacturer Hisun for Celsion’s leading oncology candidate ThermoDox, a failed Phase III study has thrown both into turmoil.
You may also be interested in...
One year after the first cases of a novel coronavirus emerged in Wuhan, a team from the World Health Organization has arrived in the city to investigate its origin. Meanwhile, mixed results are reported for some of the leading Chinese vaccines being developed to fight the pandemic still wreaking global havoc.
China's innovative drug makers step into the spotlight by grabbing green lights for cancer drugs in the country's latest batch of product approvals.
BeiGene has teamed up with Novartis to take its PD-1 antibody global after an earlier major deal with Celgene was terminated following the BMS acquisition, and amid intense market and pricing competition in the immuno-oncology sector in China.